Rapid SDH

by RapidAI (formerly iSchemaView)  · Based in United States → — Where AI meets patient care.
Emergency Medicine Neurosurgery Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor
Regulatory Status Disclosed

Overview

Rapid SDH is an AI-powered module developed by RapidAI (formerly iSchemaView) for the detection and notification of suspected hemispheric acute and chronic subdural hematoma (SDH) on non-contrast CT scans. This radiological computer-assisted triage and notification software provides critical information to clinicians in one minute or less, aiding in time-sensitive treatment decisions for trauma patients and those with hemorrhagic stroke. It boasts a high positive predictive value of 99% (93% sensitivity, 99% specificity) for SDHs greater than 1ml. Rapid SDH integrates with the Rapid mobile app, PACS, and email to send automated notifications, streamlining workflow and expediting patient care across hospital systems. It is part of RapidAI’s comprehensive hemorrhagic and trauma care AI solution.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered detection of suspected hemispheric acute and chronic subdural hematoma (SDH)
  • Notifications to clinicians in one minute or less
  • High positive predictive value (PPV) of 99% (93% sensitivity, 99% specificity) for SDHs >1ml
  • Integration with Rapid mobile app, PACS, and email for notifications
  • Part of a comprehensive hemorrhagic and trauma care AI solution (with Rapid ICH and Rapid Hyperdensity)
  • Analyzes non-contrast CT scans
  • Aids in streamlining decision-making and expediting patient care
  • Supports identification of treatment eligibility

Use Cases

  • Triage and notification of suspected subdural hematoma
  • Expediting treatment decisions for traumatic brain injury and hemorrhagic stroke patients
  • Workflow management for radiologists and neurocritical care teams
  • Facilitating patient transfer and treatment decisions across hospital systems
  • Improving patient outcomes in neurocritical care

What Physicians Need to Know

Brain MRI/CT Analysis
Rapid SDH is an AI-powered module designed for the detection and notification of suspected hemispheric acute and chronic subdural hematomas (SDH) on non-contrast CT scans. It leverages AI trained on hundreds of patient scans to identify these conditions. The software offers a sensitivity of 92.4% and specificity of 98.7% for SDH detection, with a positive predictive value of 99% for suspected acute and chronic hemispheric SDHs greater than 1 mL. It can detect both acute and chronic subdural hematomas.
Triage Prioritization Speed
Rapid SDH can scan a brain CT and return results to clinicians within one minute or less. The median processing time for SDH detection is approximately 45 seconds.
Mobile Notification System
Rapid SDH automatically sends results and notifications to the entire trauma team through the RapidAI mobile app, email, and integration with hospital PACS systems. This allows for remote triaging and faster decision-making for patient transfer and treatment.
Physician Tip

Rapid SDH provides fast and accurate detection of acute and chronic subdural hematomas on non-contrast CT scans, which can expedite diagnosis and treatment. The automated notifications via mobile app, email, and PACS can help streamline communication and decision-making among trauma teams, especially in time-sensitive situations. This tool can be used alongside other RapidAI modules like Rapid ICH and Rapid Hyperdensity for a comprehensive assessment of hemorrhagic and traumatic brain injuries.

Rapid SDH integrates with hospital PACS systems. It is part of the RapidAI platform, which offers a suite of tools for neurocritical assessment. The platform is designed for secure, vendor-agnostic integration into existing hospital IT infrastructure.

Details

Category Neurology AI, Radiology & Imaging AI, Triage & ER/ICU AI
Pricing Contact vendor
DeploymentCloud-based, On-premise
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Yes AI-estimated
Integrations
EHR Not specified
Specialties Emergency Medicine, Neurosurgery, Radiology

What the Web Says

Rapid SDH by RapidAI is an AI-powered module designed for the rapid detection and notification of suspected hemispheric acute and chronic subdural hematomas (SDH) from non-contrast CT scans. It aims to streamline decision-making and expedite patient care in neurocritical care settings. The module has received FDA clearance and boasts high sensitivity and specificity rates for detecting SDH.

Overall: Positive

Strengths

  • Rapid detection and notification of suspected SDH within one minute.
  • High sensitivity (93%) and specificity (99%) for detecting hemispheric acute and chronic SDH >1 mL.
  • Automated notifications sent via mobile app, PACS, and email to the entire trauma team, facilitating multidisciplinary collaboration.
  • Leverages AI trained on hundreds of patient scans for accurate identification of subdural hemorrhage.
  • Part of a comprehensive hemorrhagic and trauma care AI solution, including modules for ICH and Hyperdensity.
  • Aids in faster and more informed transfer and treatment decisions for patients with traumatic brain injury or hemorrhagic stroke.

Limitations

No significant limitations found in public reviews. Consider checking vendor documentation or requesting a demo for a thorough evaluation.

Based on reviews from: mdpi.com, elifesciences.org, ntt-review.jp, who.int, nih.gov, diagnosticimaging.com, researchgate.net, auntminnie.com, appliedradiology.com, fiercebiotech.com, healthaidb.com, neuronewsinternational.com, rapidai.com, businesswire.com, hitconsultant.net, capterra.com, reddit.com, medicaldevice-network.com

Last updated: 2026-10-30

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Rapid SDH

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

rapidai.com
RapidAI Receives FDA Clearance of AI Module for Detection of Hemispheric Subdural Hematomas
RapidAI announced on November 9, 2023, that it received FDA clearance for Rapid SDH, an AI-powered module designed to detect and notify suspected hemispheric acute and chronic subdural hematomas. This module is part of RapidAI's hemorrhagic and trauma care AI solution, which also includes Rapid ICH and Rapid Hyperdensity, aiming to streamline decision-making and expedite patient care.
2023-11
appliedradiology.com
RapidAI Nets FDA Clearance for AI Module That Detects Hemispheric Subdural Hematomas
The US FDA cleared Rapid SDH, an AI-powered module from RapidAI for the detection and notification of suspected hemispheric acute and chronic subdural hematoma, on November 13, 2023. This clearance enhances RapidAI's hemorrhagic and trauma care AI solution, which aims to improve patient assessment and care in the face of rising SDH cases and neurosurgical workforce shortages.
2023-11
auntminnie.com
Rapid AI gets FDA nod for Rapid SDH
RapidAI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Rapid SDH on November 9, 2023, an AI-powered module for detecting suspected hemispheric acute and chronic subdural hematoma. The system automatically sends results to the trauma team via the Rapid mobile app, PACS, and email, with a positive predictive value of 99% for suspected hematomas greater than 1mL.
2023-11
g-medtech.com
RapidAI Receives FDA Clearance of Rapid SDH for Detection Of Hemispheric Subdural Hematomas
RapidAI received FDA clearance for Rapid SDH on November 13, 2023, an AI module for the detection of hemispheric subdural hematomas. This development is part of a trend of new medical technology clearances, including augmented reality navigation systems for neurosurgery.
2023-11
rapidai.com
RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM
RapidAI announced on February 12, 2024, the publication of the TIMELESS trial in the New England Journal of Medicine (NEJM), alongside other research presented at the International Stroke Conference (ISC). The company highlighted the role of Rapid SDH in identifying patients suitable for MMA procedures, emphasizing the importance of clinical validation in AI tools.
2024-02
businesswire.com
RapidAI Receives FDA Clearance of AI Module for Detection of Hemispheric Subdural Hematomas
RapidAI, a leader in AI and technology workflow solutions for life-threatening neurovascular conditions, announced on November 9, 2023, FDA clearance for Rapid SDH. This AI-powered module detects and notifies suspected hemispheric acute and chronic subdural hematomas, further enhancing their comprehensive trauma care solution.
2023-11
itnonline.com
RapidAI Receives FDA Clearance of AI Module for Detection of Hemispheric Subdural Hematomas
On November 9, 2023, RapidAI announced FDA clearance for Rapid SDH, an AI module designed to detect hemispheric subdural hematomas, which is part of their broader hemorrhagic and trauma care AI solution. The system aims to provide faster results, notifying clinicians in one minute or less, and automatically sending notifications to the trauma team.
2023-11
neuronewsinternational.com
RapidAI Receives FDA Clearance of AI Module for Detection of Hemispheric Subdural Hematomas
RapidAI announced on November 9, 2023, that it received FDA clearance for Rapid SDH, an AI-powered module for detecting and notifying suspected hemispheric acute and chronic subdural hematomas. This module, along with Rapid ICH and Rapid Hyperdensity, forms a comprehensive AI solution for hemorrhagic and trauma care, addressing the urgent need for improved patient assessment and decision-making.
2023-11

Videos

Product demos, reviews, and walkthroughs for Rapid SDH.

Loading videos...

View all on YouTube

Frequently Asked Questions

Rapid SDH is an AI-powered module designed to quickly detect and notify clinicians of suspected hemispheric acute and chronic subdural hematomas on non-contrast CT scans. It leverages AI to analyze patient scans and aims to help neurocritical care teams identify subdural hemorrhages faster and with higher accuracy than traditional methods. The system can send notifications to the entire trauma team via a mobile app, PACS, and email within one minute, facilitating timely treatment and transfer decisions for patients with traumatic brain injury or hemorrhagic stroke.
Rapid SDH has demonstrated a sensitivity of 92.4% and a specificity of 98.7% for the detection of subdural hematomas. It boasts a positive predictive value (PPV) of 99% for suspected acute and chronic hemispheric subdural hematomas greater than 1 mL. The system is designed to provide results and notifications to clinicians in one minute or less.
Rapid SDH has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This clearance allows the module to be used in U.S. hospitals for the detection and notification of suspected hemispheric acute and chronic subdural hematoma.
While traditional methods involve manual interpretation of CT scans, AI solutions like Rapid SDH aim to expedite this process. RapidAI also offers other AI-powered modules such as Rapid ICH and Rapid Hyperdensity for detecting intracranial hemorrhage and hyperdense areas, forming a comprehensive hemorrhagic and trauma care AI solution. In a head-to-head study (DUEL study) comparing Rapid LVO to Viz LVO software for large vessel occlusion detection, Rapid LVO showed superior accuracy. However, the specific comparison of Rapid SDH to other AI-powered SDH detection tools was not detailed in the provided information.
The provided information does not explicitly detail specific limitations of Rapid SDH. However, AI tools are generally designed to assist clinicians and not replace their judgment. The accuracy metrics provided (sensitivity 92.4%, specificity 98.7%, PPV 99%) indicate a high level of performance, but like all diagnostic tools, it is not 100% perfect.
Rapid SDH integrates into existing hospital workflows by automatically sending results and notifications through the Rapid mobile app, Picture Archiving and Communication Systems (PACS), and email. This facilitates communication among the trauma team and helps streamline decision-making and patient care. RapidAI aims for an efficient implementation workflow, often taking a team from start to live within two weeks.

Compare Rapid SDH

VS
Rapid SDH vs Viz Subdural+
Clinical Decision Support & Reference Direct · 90/100
Both Rapid SDH and Viz Subdural+ are FDA-cleared AI tools designed for the detection of acute and chronic subdural hematomas on non-contrast CT scans, aiming to expedite neurocritical…
VS
Rapid SDH vs HealthPNX
Clinical Decision Support & Reference Adjacent · 65/100
Both Rapid SDH and HealthPNX are FDA-cleared AI solutions designed to enhance clinical decision-making through rapid detection and automated alerts. Rapid SDH specializes in identifying subdural hematomas on…
VS
Rapid SDH vs Viz CTP
Clinical Decision Support & Reference Adjacent · 70/100
Rapid SDH is a specialized AI tool focused solely on the rapid detection and notification of subdural hematomas on CT scans. Viz CTP is a broader AI platform…
VS
Rapid SDH vs Viz HCM
Clinical Decision Support & Reference Adjacent · 65/100
Both Rapid SDH and Viz HCM are FDA-cleared AI tools aimed at clinical decision support and care coordination. Rapid SDH is designed for the rapid detection of subdural…

Related Tools

Parkiwatch
Koios Care
Neurology AI
Parkiwatch by Koios Care is a Class IIa Software as a Medical Device (EU MDR 2017/745) for continuous, passive detection and quantitative assessment of kinematic patterns representative of tremor, bradykinesia, and dyskinesia in adults with Parkinson's Disease.
Paid
CortiCare (Virtual EEG Department)
CortiCare
Neurology AI
CortiCare offers 24/7 remote EEG monitoring and interpretation services, functioning as a virtual EEG department to assist hospitals and neurology practices in identifying seizures and other neurological conditions.
NeuroAstra
Avinya NeuroTech
Clinical Decision Support & Reference
NeuroAstra is an AI-enabled EEG analysis and reporting software that provides a multimodal clinical EEG web platform with Co-Pilot AI to help neuro care teams detect abnormal trends faster and standardize reporting.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Paid

See all Neurology AI tools →

More from RapidAI (formerly iSchemaView)

iSchemaView RAPID
RapidAI (formerly iSchemaView)
Neurology AI
RapidAI is an AI-enabled software platform that facilitates the viewing, processing, and analysis of CT and MRI imaging to aid clinicians in assessing patients with suspected stroke, providing automated results for faster, more accurate diagnostic and treatment decisions.
Contact for pricing
Rapid
RapidAI
Neurology AI
RapidAI is an AI-driven medical imaging analysis and coordinated care platform that empowers healthcare teams to rapidly, precisely, and confidently manage life-threatening conditions, especially acute stroke, through advanced CT and MRI image processing.
Rapid CTA 360
RapidAI
Neurology AI
Rapid CTA 360 by RapidAI (formerly iSchemaView) is an AI-powered imaging solution providing automated 3D CTA reconstructions for rapid and precise stroke diagnosis and treatment planning, enhancing visibility of occlusions and collateral flow.
Rapid LVO
RapidAI (formerly iSchemaView)
Neurology AI
Rapid LVO by RapidAI is an FDA-cleared AI tool for the fast and accurate detection of Large Vessel Occlusions (LVOs) in acute stroke patients using CTA imaging, streamlining triage and care coordination.
Contact vendor for pricing.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.